Capital Fund Management (CFM)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.41M Sell
228,800
-313,100
-58% -$14.8M 0.04% 630
2025
Q4
$27.6M Sell
541,900
-145,500
-21% -$7.44M 0.08% 351
2025
Q3
$38.1M Buy
687,400
+56,400
+9% +$3.3M 0.1% 266
2025
Q2
$43.6M Sell
631,000
-229,700
-27% -$15.6M 0.12% 240
2025
Q1
$59.8M Buy
860,700
+553,500
+180% +$45.7M 0.17% 162
2024
Q4
$26.4M Buy
307,200
+131,400
+75% +$14.2M 0.07% 389
2024
Q3
$20.9M Buy
175,800
+59,500
+51% +$7.94M 0.06% 436
2024
Q2
$16.6M Buy
116,300
+41,000
+54% +$5.43M 0.05% 479
2024
Q1
$9.67M Sell
75,300
-370,900
-83% -$44.2M 0.03% 749
2023
Q4
$46.2M Buy
446,200
+421,400
+1,699% +$41.7M 0.12% 223
2023
Q3
$2.26M Buy
+24,800
New +$2.18M 0.01% 1293
2021
Q4
Sell
-59,800
Closed -$2.87M 1772
2021
Q3
$2.87M Buy
+59,800
New +$2.89M 0.02% 783
2018
Q3
Sell
-13,600
Closed -$314K 2168
2018
Q2
$314K Sell
13,600
-27,800
-67% -$661K ﹤0.01% 1769
2018
Q1
$1.02M Buy
+41,400
New +$1.09M 0.01% 1228
2017
Q4
Sell
-20,600
Closed -$496K 1929
2017
Q3
$496K Buy
+20,600
New +$466K ﹤0.01% 1180

Other funds holding NVO

Capital Fund Management (CFM)'s NVO Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Novo Nordisk (NVO) stake by 303% in Q1 2026, buying an estimated $19.6M and bringing the position to 549,373 shares worth $20.2M. The position accounts for 0.09% of the portfolio, ranked #307.

Capital Fund Management (CFM) first reported a position in NVO in Q2 2013 and has held it in 41 quarters since. The position peaked at $98.7M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Capital Fund Management (CFM) held 549,373 shares of Novo Nordisk worth $20.2M as of Q1 2026.
  • Capital Fund Management (CFM) bought 413,171 Novo Nordisk shares in Q1 2026, an estimated $19.6M.
  • Novo Nordisk made up 0.09% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #307 holding.
  • Capital Fund Management (CFM) first reported a position in Novo Nordisk in Q2 2013 and has held it in 41 quarters since.
  • Capital Fund Management (CFM)'s Novo Nordisk position peaked at $98.7M in Q1 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.